Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells.

Aguilera-Montilla N, Bailón E, Ugarte-Berzal E, Uceda-Castro R, Prieto-Solano M, García-Martínez E, Samaniego R, Van den Steen PE, Opdenakker G, García-Marco JA, García-Pardo A.

Biochem Biophys Res Commun. 2019 Nov 26;520(1):198-204. doi: 10.1016/j.bbrc.2019.09.127. Epub 2019 Oct 1.

PMID:
31585732
2.

α4β1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling.

Gutiérrez-González A, Aguilera-Montilla N, Ugarte-Berzal E, Bailón E, Cerro-Pardo I, Sánchez-Maroto C, García-Campillo L, García-Marco JA, García-Pardo A.

Blood Adv. 2019 Jul 23;3(14):2144-2148. doi: 10.1182/bloodadvances.2019000019. No abstract available.

3.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group.

Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19.

4.

MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest.

Aguilera-Montilla N, Bailón E, Uceda-Castro R, Ugarte-Berzal E, Santos A, Gutiérrez-González A, Pérez-Sánchez C, Van den Steen PE, Opdenakker G, García-Marco JA, García-Pardo A.

Oncogene. 2019 Jun;38(23):4605-4619. doi: 10.1038/s41388-019-0744-3. Epub 2019 Feb 13.

PMID:
30760844
5.

Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia.

González-Rincón J, Gómez S, Martinez N, Troulé K, Perales-Patón J, Derdak S, Beltrán S, Fernández-Cuevas B, Pérez-Sanz N, Nova-Gurumeta S, Gut I, Al-Shahrour F, Piris MA, García-Marco JA, Sánchez-Beato M.

Sci Rep. 2019 Jan 30;9(1):975. doi: 10.1038/s41598-018-37389-7.

6.

A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways.

Bailón E, Aguilera-Montilla N, Gutiérrez-González A, Ugarte-Berzal E, Van den Steen PE, Opdenakker G, García-Marco JA, García-Pardo A.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):124-130. doi: 10.1016/j.bbrc.2017.10.129. Epub 2017 Nov 4.

PMID:
29080742
7.

Minimal residual disease in chronic lymphocytic leukaemia.

García Vela JA, García Marco JA.

Med Clin (Barc). 2018 Feb 23;150(4):144-149. doi: 10.1016/j.medcli.2017.06.067. Epub 2017 Aug 31. Review. English, Spanish.

PMID:
28864095
8.

Prostatic-Like Syndrome in a Woman with Chronic Lymphocytic Leukemia: Sequential Kinase Inhibitor Therapy.

Velasco-Rodríguez D, Piris-Villaespesa M, Soteras C, Vallés A, García-Marco JA, García-Vela JA.

Case Rep Hematol. 2017;2017:3869020. doi: 10.1155/2017/3869020. Epub 2017 Jul 2.

9.

Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.

García-Marco JA, Delgado J, Hernández-Rivas JA, Ramírez Payer Á, Loscertales Pueyo J, Jarque I, Abrisqueta P, Giraldo P, Martínez R, Yáñez L, Terol MJ, González M, Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC).

Med Clin (Barc). 2017 Apr 21;148(8):381.e1-381.e9. doi: 10.1016/j.medcli.2016.12.030. Epub 2017 Feb 22. English, Spanish.

PMID:
28236475
10.

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U.

Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15.

11.

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.

Sánchez-Martínez D, Lanuza PM, Gómez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martínez-Lostao L, Villalba M, Palomera L, Vilches C, García Marco JA, Pardo J.

Front Immunol. 2016 Oct 27;7:454. eCollection 2016.

12.

Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9.

Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, García-Marco JA, García-Pardo A.

Oncotarget. 2016 Dec 13;7(50):83359-83377. doi: 10.18632/oncotarget.13091.

13.

Growth differentiation factor 11 (GDF11) - a promising anti-ageing factor - is highly concentrated in platelets.

Bueno JL, Ynigo M, de Miguel C, Gonzalo-Daganzo RM, Richart A, Vilches C, Regidor C, García-Marco JA, Flores-Ballester E, Cabrera JR.

Vox Sang. 2016 Nov;111(4):434-436. doi: 10.1111/vox.12438. Epub 2016 Aug 10.

PMID:
27509407
14.

Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.

Lozano-Santos C, García-Vela JA, Pérez-Sanz N, Nova-Gurumeta S, Fernandez-Cuevas B, Gomez-Lozano N, Sánchez-Beato M, Sanchez-Godoy P, Bueno JL, Garcia-Marco JA.

Leuk Lymphoma. 2017 Apr;58(4):859-865. doi: 10.1080/10428194.2016.1213829. Epub 2016 Aug 8.

PMID:
27499002
15.

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

Montesinos P, Cabrero M, Valcárcel D, Rovira M, García-Marco JA, Loscertales J, Moreno C, Duarte R, Terol MJ, Villamor N, Abrisqueta P, Caballero D, Sanz J, Delgado J.

Bone Marrow Transplant. 2016 Oct;51(10):1404-1407. doi: 10.1038/bmt.2016.145. Epub 2016 May 23. No abstract available.

PMID:
27214073
16.

Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.

González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group.

Ann Hematol. 2016 May;95(6):893-9. doi: 10.1007/s00277-016-2648-4. Epub 2016 Mar 30.

17.

In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Martínez-Moreno M, Leiva M, Aguilera-Montilla N, Sevilla-Movilla S, Isern de Val S, Arellano-Sánchez N, Gutiérrez NC, Maldonado R, Martínez-López J, Buño I, García-Marco JA, Sánchez-Mateos P, Hidalgo A, García-Pardo A, Teixidó J.

Leukemia. 2016 Apr;30(4):861-72. doi: 10.1038/leu.2015.332. Epub 2015 Dec 10.

18.

Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.

Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.

Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.

19.

Current and emerging treatment options for hairy cell leukemia.

López-Rubio M, Garcia-Marco JA.

Onco Targets Ther. 2015 Aug 19;8:2147-56. doi: 10.2147/OTT.S70316. eCollection 2015. Review.

20.

Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.

Lozano-Santos C, Amigo-Jiménez I, Nova-Gurumeta S, Pérez-Sanz N, García-Pardo A, García-Marco JA.

Biochem Biophys Res Commun. 2015 May 29;461(2):243-8. doi: 10.1016/j.bbrc.2015.04.007. Epub 2015 Apr 11.

PMID:
25869069
21.

Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).

Martino R, Bautista G, Parody R, García I, Esquirol A, Rovira M, Cabrera JR, Regidor C, Fores R, García-Marco JA, Serrano D, Barba P, Heras I, Marquez-Malaver FJ, Sánchez-Ortega I, Duarte R, Saavedra S, Sierra J, Vazquez L; Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético.

Transpl Infect Dis. 2015 Apr;17(2):221-33. doi: 10.1111/tid.12361.

PMID:
25652036
22.

Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.

Onaindia A, Gómez S, Piris-Villaespesa M, Martínez-Laperche C, Cereceda L, Montes-Moreno S, Batlle A, de Villambrosia SG, Pollán M, Martín-Acosta P, González-Rincón J, Menarguez J, Alvés J, Rodriguez-Pinilla SM, García JF, Mollejo M, Fraga M, García-Marco JA, Piris MA, Sánchez-Beato M.

Haematologica. 2015 May;100(5):e200-3. doi: 10.3324/haematol.2014.117705. Epub 2014 Dec 31. No abstract available.

23.

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.

Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.

Br J Haematol. 2015 Apr;169(2):188-98. doi: 10.1111/bjh.13273. Epub 2014 Dec 18.

PMID:
25521006
24.

Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders.

Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega I, Serrano D, Anguita J, Buño I, Fores R, Regidor C, García Marco JA, Vilches C, de Pablo R, Fernández MN, Gayoso J, Duarte R, Díez-Martín JL, Cabrera R.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2015-22. doi: 10.1016/j.bbmt.2014.08.024. Epub 2014 Sep 22.

25.

Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.

Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, Van den Steen P, Opdenakker G, García-Marco JA, García-Pardo A.

J Leukoc Biol. 2014 Aug;96(2):185-99. doi: 10.1189/jlb.3HI0913-521R.

PMID:
25080557
26.

[Mantle cell lymphoma: Towards a personalized therapeutic strategy?].

Navarro Matilla B, García-Marco JA.

Med Clin (Barc). 2015 Jun 22;144(12):553-9. doi: 10.1016/j.medcli.2014.04.025. Epub 2014 Jul 12. Review. Spanish.

PMID:
25023849
27.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO).

Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. No abstract available.

28.

Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.

Lozano-Santos C, Martinez-Velasquez J, Fernandez-Cuevas B, Polo N, Navarro B, Millan I, Garcia JM, Collado R, Sanchez-Godoy P, Carbonell F, Garcia-Vela JA, Garcia-Marco JA, Gomez-Lozano N.

PLoS One. 2014 Jun 27;9(6):e101063. doi: 10.1371/journal.pone.0101063. eCollection 2014.

29.

Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.

Amigo-Jiménez I, Bailón E, Ugarte-Berzal E, Aguilera-Montilla N, García-Marco JA, García-Pardo A.

PLoS One. 2014 Jun 23;9(6):e99993. doi: 10.1371/journal.pone.0099993. eCollection 2014.

30.

A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.

Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, Albar JP, García-Marco JA, García-Pardo A.

J Biol Chem. 2014 May 30;289(22):15340-9. doi: 10.1074/jbc.M114.559187. Epub 2014 Apr 16.

31.

HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.

Forés R, Dorado N, Vilches C, Regidor C, García-Marco JA, de Pablo R, de Laiglesia A, Lario A, Piris M, Cabrera JR.

Br J Haematol. 2014 May;165(4):580-1. doi: 10.1111/bjh.12771. Epub 2014 Feb 20. No abstract available.

PMID:
24666200
32.

Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.

Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, Van den Steen P, Opdenakker G, García-Marco JA, García-Pardo A.

J Leukoc Biol. 2014 Mar 11. [Epub ahead of print]

PMID:
24620030
33.

PLCG1 mutations in cutaneous T-cell lymphomas.

Vaqué JP, Gómez-López G, Monsálvez V, Varela I, Martínez N, Pérez C, Domínguez O, Graña O, Rodríguez-Peralto JL, Rodríguez-Pinilla SM, González-Vela C, Rubio-Camarillo M, Martín-Sánchez E, Pisano DG, Papadavid E, Papadaki T, Requena L, García-Marco JA, Méndez M, Provencio M, Hospital M, Suárez-Massa D, Postigo C, San Segundo D, López-Hoyos M, Ortiz-Romero PL, Piris MA, Sánchez-Beato M.

Blood. 2014 Mar 27;123(13):2034-43. doi: 10.1182/blood-2013-05-504308. Epub 2014 Feb 4.

PMID:
24497536
34.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO.

Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25.

35.

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F.

Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11.

PMID:
24124086
36.

Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).

López Rubio M, Da Silva C, Loscertales J, Seri C, Baltasar P, Colado E, Pérez Fernández I, Osma M, Gomis F, González M, Jarque I, Vargas M, Monzó E, Monteagudo D, Orts MI, Pardal E, Carbonell F, Perez Calvo C, Garcia-Marco JA.

Leuk Lymphoma. 2014 May;55(5):1007-12. doi: 10.3109/10428194.2013.827187. Epub 2013 Sep 16.

PMID:
23885799
37.

[National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Espan˜ola de Hematologı´a y Hemoterapia and Grupo Espan˜ol de Leucemia Linfocı´tica Cro´ nica].

García Marco JA, Giraldo Castellano P, López Jiménez J, Ríos Herranz E, Sastre Moral JL, Terol Casterá MJ, Bosch Albareda F; en representación del Grupo Español de Leucemia Linfática Crónica (GELLC); Sociedad Espan˜ola de Hematologı´a y Hemoterapia.

Med Clin (Barc). 2013 Aug 17;141(4):175.e1-8. doi: 10.1016/j.medcli.2013.04.041. Epub 2013 Jul 3. Spanish.

PMID:
23830547
38.

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D.

Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377. Epub 2013 Jun 10.

39.

A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, Vituri CL, del Cerro MH, Terol MJ, Albar JP, Rivas G, García-Marco JA, García-Pardo A.

J Biol Chem. 2012 Aug 10;287(33):27601-13. doi: 10.1074/jbc.M112.354670. Epub 2012 Jun 22.

40.

New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing.

Doménech E, Gómez-López G, Gzlez-Peña D, López M, Herreros B, Menezes J, Gómez-Lozano N, Carro A, Graña O, Pisano DG, Domínguez O, García-Marco JA, Piris MA, Sánchez-Beato M.

PLoS One. 2012;7(6):e38158. doi: 10.1371/journal.pone.0038158. Epub 2012 Jun 1.

41.

[Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].

Casado LF, García Marco JA, Gilsanz F, González M, Ríos E, de la Serna J, Urbano A, Vicente V, Rubio-Terrés C, Castro AJ.

Gac Sanit. 2011 Jul-Aug;25(4):274-81. doi: 10.1016/j.gaceta.2011.03.005. Spanish. Erratum in: Gac Sanit. 2011 Sep-Oct;25(5):444.

42.

Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.

Vallejo C, Ríos E, de la Serna J, Jarque I, Ferrá C, Sánchez-Godoy P, Solano C, de la Cámara R, Rosell AI, Varela R, García MD, González-Barca E, López J, Pérez E, Ferrer S, Casado LF, Vázquez L, Villalón L, García-Marco JA.

Expert Rev Hematol. 2011 Feb;4(1):9-16. doi: 10.1586/ehm.10.77.

PMID:
21322774
43.

Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.

Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, Pandiella A, Terol MJ, García-Marco JA, García-Pardo A.

Clin Cancer Res. 2010 Sep 1;16(17):4382-91. doi: 10.1158/1078-0432.CCR-10-0072. Epub 2010 Jun 9.

44.

Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain.

Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernández del Cerro M, Roderfeld M, Roeb E, Opdenakker G, García-Marco JA, García-Pardo A.

Cancer Cell. 2010 Feb 17;17(2):160-72. doi: 10.1016/j.ccr.2009.12.044.

45.

Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.

Espinet B, Salaverria I, Beà S, Ruiz-Xivillé N, Balagué O, Salido M, Costa D, Carreras J, Rodríguez-Vicente AE, Luís García J, Hernández-Rivas JM, Calasanz MJ, Siebert R, Ferrer A, Salar A, Carrió A, Polo N, García-Marco JA, Domingo A, González-Barca E, Romagosa V, Marugán I, López-Guillermo A, Millá F, Luís Mate J, Luño E, Sanzo C, Collado R, Oliver I, Monzó S, Palacín A, González T, Sant F, Salinas R, Ardanaz MT, Font L, Escoda L, Florensa L, Serrano S, Campo E, Solé F.

Genes Chromosomes Cancer. 2010 May;49(5):439-51. doi: 10.1002/gcc.20754.

PMID:
20143418
46.

CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.

Citores MJ, Castejon R, Villarreal M, Rosado S, Garcia-Marco JA, Vargas JA.

Exp Hematol. 2010 Mar;38(3):165-73. doi: 10.1016/j.exphem.2009.12.001. Epub 2009 Dec 22.

PMID:
20026377
47.

VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.

Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, Del Cerro MH, García-Marco JA, Terol MJ, García-Pardo A.

Blood. 2010 Jan 28;115(4):846-9. doi: 10.1182/blood-2009-08-239426. Epub 2009 Nov 19.

48.

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.

J Clin Oncol. 2009 Sep 20;27(27):4578-84. doi: 10.1200/JCO.2009.22.0442. Epub 2009 Aug 24.

PMID:
19704063
49.

Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.

Castejón R, Yebra M, Citores MJ, Villarreal M, García-Marco JA, Vargas JA.

Leuk Lymphoma. 2009 Apr;50(4):593-603. doi: 10.1080/10428190902780669.

PMID:
19373658
50.

Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.

Gonzalo-Daganzo R, Regidor C, Martín-Donaire T, Rico MA, Bautista G, Krsnik I, Forés R, Ojeda E, Sanjuán I, García-Marco JA, Navarro B, Gil S, Sánchez R, Panadero N, Gutiérrez Y, García-Berciano M, Pérez N, Millán I, Cabrera R, Fernández MN.

Cytotherapy. 2009;11(3):278-88. doi: 10.1080/14653240902807018.

PMID:
19308773

Supplemental Content

Loading ...
Support Center